Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality.

Challenge

GLP-1 receptor agonists had shown promising signals in MASH but real-world data on their actual use patterns, tolerability, and association with outcomes in the heterogeneous MASLD population receiving usual care—including those with cirrhosis—were essentially absent.

Solution

The TARGET-NASH cohort was used to characterize GLP-1 RA use prevalence, duration, patient demographics, reasons for discontinuation, and association with all-cause mortality across MASLD disease phenotypes in a cross-sectional analysis spanning thousands of real-world patients.

Impact

Providing the first large-scale real-world characterization of GLP-1 RA use in MASLD establishes real-world effectiveness context for ongoing GLP-1 clinical programs and informs the design of comparative effectiveness studies assessing GLP-1 RAs as MASLD-modifying therapies.